Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)

NCT07400653 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07400653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07400653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 24, 2026
Completion date
May 16, 2028
Enrollment
1,078 (actual)
Sites
180

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, type 2, obesity, overweight, overweight and/or obesity, type 2 diabetes